Q1 Financials; MUIR Upcoming, But We See DENALI on the Horizon

Research evidence excerpt

Q1 Financials; MUIR Upcoming, But We See DENALI on the Horizon

Company Report

May 13, 2026 Zentalis Pharmaceuticals, Inc. (ZNTL)

Rating: Q1 Financials; MUIR Upcoming, But We See DENALI on theNEUTRAL HorizonPrice:

$4.28

12-Month Price Target: The Wedbush View

$4.00

ZNTL reported first quarter financials and provided corporate updates ahead of

Analysts MUIR Part 1 data upcoming at the ASCO Annual Meeting on June 1st (3107).

Robert Driscoll, Ph.D. As a reminder, the readout will include data investigating azenosertib + paclitaxel

(415) 274-6863 in 2L+ all-comer patients with PROC; ZNTL is also currently enrolling 2L PARPi-Robert.Driscoll@wedbush.com progressed, platinum-sensitive patients to receive azeno + bevacizumab in a doseGeoffrey Von Der Ahe

(628) 223-0517 escalation portion of MUIR Part 2. Beyond MUIR, topline data for DENALI Part 2

geoffrey.vonderahe@wedbush.com remains on track for YE:26, which could support accelerated approval in the Cyclin

E1-selected patient population; we believe this is attainable, given chemotherapy

has historically resulted in <15% ORR and <4 month mPFS in PROC (Eskander et

Company Information al., 2023; company data). As a reminder, ZNTL recently announced the selection

Market Cap (M) $294 of the 400 mg QD, 5 days on/2 days off (5:2) as the pivotal study dose movingEnterprise Value (M) $72

Shares Outst (M) 70.3 forward in DENALI Part 2a (see our note, here); while details on data between the

52-Week Range $1.13 - $6.95 two doses investigated in Part 2a were not disclosed, ZNTL reported differentiated

Cash/sh $3.01 responses, among comparable safety profiles, between the 400 and 300 mg dose

Net Debt (M) $(211.80) levels. Importantly, the company announced treatment related discontinuations